Recurrence Hepatocellular Carcinoma: Patterns, Detection, Staging and Treatment

Dimitrios Papaconstantinou, Diamantis I Tsilimigras, Timothy M Pawlik

Abstract: Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths worldwide with the incidence of recurrence being as high as 88% even among patients who have undergone curative-intent treatment. Despite improvements in overall survival, recurrence remains a challenge necessitating accurate reappraisal of patient and disease status. To that end, accurate staging of recurrent HCC is a necessity to provide better care for these patients. Risk factors for poor survival after HCC recurrence have been identified and include characteristics of the primary disease, such as tumor multifocality, large size (≥5 cm), macroscopic vascular or microscopic lymphovascular invasion, preoperative a-fetoprotein (AFP) levels, R0 resection, and the presence of impaired liver function. Close surveillance with imaging is warranted following curative-intent therapy, with magnetic resonance imaging (MRI) being the preferred approach to identify small, early recurrent HCCs. Treatment decisions at the time of recurrence involve ruling out extrahepatic disease and identifying candidates for potentially curative-intent repeat treatment options. Patients with recurrent disease are, however, very diverse in terms of tumor morphology and biologic behavior, as well as residual hepatic functional reserve. Patients with preserved liver function may benefit from repeat liver resection or ablation. Patients with recurrence within the Milan criteria may even be candidates for salvage liver transplantation, while multimodality treatment with combination of liver-directed therapies appears to enhance oncologic outcomes for individuals with advanced recurrent disease. A "one-size-fits-all" approach in staging recurrent HCC does not exist. Rather, individualized and evidence-based decision-making is necessary in order to optimize outcomes for patients with recurrent HCC.

Keywords: hepatocellular carcinoma, recurrence, staging, treatment, classification

Introduction

Hepatocellular carcinoma (HCC) is the principal histologic type of liver cancer, accounting for the majority of liver malignancies and constituting the third most common cause of cancer-related death worldwide. Unlike most other common malignancies, HCC is unique as it features two coexisting disease components; the first disease process relates to the primary tumor and its associated characteristics, while the second clinical consideration involves the underlying liver disease (ie, liver cirrhosis/fibrosis and/or hepatitis B/C infection). Consequently, choice of treatment strategies can often be limited due to insufficient liver function reserve. In addition, outcomes related to various treatment options can vary significantly based on different clinicopathologic factors including underlying liver function, tumor size, vascular invasion, as well as genetic variants related to tumor biology.

Irrespective of etiology and treatment strategy, HCC can often recur. As such, close post-operative surveillance is warranted, and, when recurrence is detected, reassessment of disease status and treatment options is necessary. Optimal staging schemas for recurrent HCC have not been well documented in the literature compared with staging systems related to primary HCC. Treatment algorithms, staging systems, and data on management of recurrent HCC are critical to guide clinical decisions. In part due to advances in early diagnosis, as well as optimization of treatment options, patients with recurrent HCC now have better prognosis and tend to live longer.
The optimal staging strategy for recurrent HCC should incorporate as much disease-relevant information as possible. Staging schemes related to recurrent HCC should, in principle, take into account tumor-specific characteristics (i.e., size and number of nodules, site of recurrence, as well as other pathologic characteristics indicative of aggressiveness), the extent of underlying liver disease (i.e., liver cirrhosis based on imaging and functional studies and hepatitis viral activity), and also details regarding previous treatments. Moreover, the optimal staging system should allow for prognostic stratification of patients, as well as enable treatment allocation. In this context, further investigation of the epidemiologic, biologic, and clinical features of recurrent HCC is essential.

Patterns of HCC Recurrence and Risk Factors

HCC is a disease that exhibits marked geographic variability in terms of incidence, largely due to differences in the prevalence of underlying risk factors. In particular, the disease burden is higher in areas with endemic hepatitis B (HBV) such as East Asia and sub-Saharan Africa, while hepatitis C (HCV) and non-alcoholic fatty liver disease (NAFLD) are prominent risk factors for HCC in Europe, North America, and Japan. Although such differences in chronic liver disease etiologies would be expected to give rise to diverse disease phenotypes with varying recurrence patterns, no clear association with disease aggressiveness has been established. Instead, the presence of cirrhosis and/or fibrosis, which is the ultimate biologic endpoint of all liver disease processes if left untreated, has previously been linked to poor overall and disease-free survival outcomes. In particular, the presence of cirrhosis can lead to an increased risk of HCC recurrence.

Globally, there has been a trend towards an increased incidence of HCC, likely due to an increased incidence of HCV infections and NAFLD, which has been slightly offset by the decrease of HBV infection incidence in East Asia, as antiviral treatments become more widely available. Data on temporal trends related to the incidence of HCC recurrence are sparse. A recent meta-analysis by Tan et al, which reported on transplanted patients, reported that the incidence of HCC recurrence following transplantation decreased over time, although this finding was not statistically significant. In the same patient population, recurrence rates seemed to follow a similar incidence pattern to that of primary tumor, with Asian populations who had higher HBV infection rates having an increased incidence of HCC recurrence.

Following initial treatment of HCC, the disease may enter a latent phase. Depending on the primary treatment utilized, patients may experience disease recurrence (i.e., after curative-intent liver resection) or disease progression (i.e., after ablation or chemomobilization). While different index treatment modalities may be associated with different risk levels of recurrent disease, patterns of HCC recurrence have been most extensively studied after resection. A recent retrospective multicentre study reported a recurrence rate of 45.5% among 756 patients who underwent curative-intent liver resection. The investigators noted that most recurrences were intrahepatic in nature, arising in the liver remnant rather than close to the resection margin; in addition, the vast majority of recurrences occurred within two years of the index operation. In a separate study by Xu et al, late recurrences (i.e., >2 years after the index procedure) were also noted to be predominantly intrahepatic (90.1%); of note, the authors reported that up to 54.5% of patients had a recurrence that was potentially amenable to repeat curative-intent treatment. In yet another study, Kim et al estimated that the hazard to develop recurrent disease peaked within the first year following hepatectomy and then gradually decreased until the fifth postoperative year, remaining stable thereafter. Similar recurrence patterns have been described after liver transplantation. Collectively, the data seemed to indicate that primary tumor clinico-morphological parameters, as well as the timing of the recurrence, are the main determinants of long-term outcomes among patients with recurrent HCC disease.

Even after treatment of recurrent disease, a large number of patients will develop a second recurrence with a reported incidence of 50–70%. Some patients may even go on to develop a third or fourth recurrence after previous curative-intent treatment. While this is uncommon, the data that are available suggest that each successive curative-intent procedure is associated with diminishing probability of long-term survival. Risk factors associated with HCC recurrence have largely been related to patient and tumor-specific parameters. For example, factors indicative of HCC aggressiveness and increased risk of recurrence have included tumor multi-nodularity, large size (≥5 cm), macroscopic vascular or microscopic lympho-vascular invasion, high preoperative a-fetoprotein (AFP) levels, as well as the presence of cirrhosis and advanced initial BCLC stage. While recurrence has largely been examined post-liver resection or liver transplantation, other authors have sought to develop composite recurrence risk scores after ablation, with some investigators employing artificial intelligence. Previous studies have largely focused on risk assessment related to survival following primary treatment; however, prognostic indicators associated with factors related to the primary HCC
tumor are unlikely to be as relevant in the setting of recurrent disease. Instead, other factors such as time to recurrence, extrahepatic spread, and size and number of recurrent nodules are likely to be more useful to estimate the overall survival (OS) and disease-free survival (DFS) after the recurrence has occurred.29–32

Detection of Recurrent Disease
Appropriately timed follow-up is key to detect HCC recurrence. Since many patients develop a recurrence early following treatment of the primary tumor,2 close surveillance is mandatory. While surveillance guidelines can vary, patients should generally be followed every 3–4 months for the first 1–3 years, every 6 months for years 3–5, and then annually to at least 10 years.3 The timing of surveillance should be informed both by primary tumor characteristics (ie, risk of recurrence), as well as the underlying liver quality itself (ie, risk of de novo disease). Surveillance generally involves contrast-enhanced multidetector computed tomography (MDCT) or magnetic resonance imaging (MRI) scanning combined with AFP level measurement.33 Detection of early recurrent disease is of paramount importance, especially given that prior treatments may have reduced the remaining liver volume and/or impaired functionality, which could limit treatment options for advanced recurrences. To this point, in a head-to-head comparison of gadoxetic-enhanced MRI versus MDCT, MRI was noted to be more sensitive to detect HCC recurrences smaller than 2 cm (96% versus 65%, respectively) and had a higher overall accuracy (97% versus 85%, respectively).34 Of note, gadoxetic acid-based MRI techniques also conferred a significant advantage in the ability to recognize early recurrence; in contrast, non-contrast enhanced MRI had comparable performance to MDCT in detecting recurrences 1 year post-hepatectomy.35

In addition to cross-sectional imaging, biomarkers also have a role in detecting recurrence following the index treatment of HCC. For example, AFP has traditionally been used as a marker of HCC recurrence, despite its relatively low sensitivity. Instead, des-γ-carboxy-prothrombin (DCP) has been reported to be superior to AFP measurements to detect HCC recurrence.36–38 To this point, DCP has been implemented into the Kyoto criteria to select transplantation candidates; however, DCP has yet to be incorporated into routine surveillance for HCC recurrence.39 Inflammatory and angiogenic markers have also been evaluated among transplanted patients.40 Furthermore, detection of circulating tumor DNA, otherwise called liquid biopsy, has also been postulated to increase the predictive performance of AFP.41 Currently, there is no “best” biomarker combination to detect early HCC recurrence with high accuracy. Novel biomarkers are, however, critically important in specific patient subgroups, such as those individuals who are AFP-negative.42

Staging and Treatment of Recurrent HCC
After establishing the diagnosis of HCC recurrence,43 staging should begin with searching for evidence of extrahepatic disease (present in 12% to 27% of patients)3,4,44 since this is largely considered a contraindication to surgical treatment. Some investigators have, however, suggested that even patients with isolated extrahepatic recurrence may still benefit from resection.45 Intrahepatic recurrences are present in the majority of patients irrespective of the primary treatment modality employed (ie, resection, transplantation, or ablation). In turn, patients with intrahepatic recurrence represent the most diverse group in terms of recurrent tumor morphology, amenability to curative-intent treatments, and biologic behavior. Although no staging schema has been established to date relative to recurrent HCC, primary HCC staging schemas, such as the BCLC classification, are often extrapolated and used to help predict outcomes and guide decision-making in the setting of recurrent HCC. Indeed, Yao et al recently investigated the applicability of BCLC staging for recurrent HCC and demonstrated distinct prognosis in terms of OS among individuals with variable recurrent HCC BCLC staging, thus validating the prognostic ability of BCLC staging in the setting of recurrent disease.46 Nevertheless, the majority of patients who recurred did not receive the treatment suggested by the BCLC algorithm in the setting of primary HCC.46 Existing staging schemas such as the BCLC and the Hong Kong Liver Cancer (HKLC) classifications were not developed to assist with prognostication or decision-making in the setting of recurrent HCC.47 In turn, these staging systems and treatment algorithms should not be applied indiscriminately to patients with recurrent disease.

In general, the presence of extrahepatic disease or portal vein thrombus, lesion size, recurrence within or beyond the Milan criteria, disease resectability, and eligibility for transplantation should all be taken into account when assessing patients with recurrent HCC. In addition, AFP levels at the time of recurrence can also predict post-recurrence survival independent of the secondary treatment modality; as such, AFP levels should routinely be evaluated when recurrence is suspected.48 Perhaps not
surprisingly, the most important determinant of long-term survival after recurrence is whether the recurrent disease is amenable to curative-intent therapy (Table 1). In a retrospective multi-center study from Italy that included 1560 patients, Famularo et al reported an increase in OS and DFS among patients who were treated with curative-intent repeat liver resection and/or ablation versus palliative TACE with or without sorafenib. Ablation has previously been demonstrated to be more effective than systemic sorafenib therapy. While TACE has also been associated with better survival outcomes than sorafenib, these data suffer from significant selection bias. While possibly providing better long-term control than TACE, ablation has limited applicability in the setting of recurrent multinodular disease. Similarly, repeat resection is also limited to patients with solitary or oligo-recurrent disease, as well as individuals with preserved liver volume and function. The treatment of recurrent HCC should be individualized and needs to take into account the location and extent of recurrent disease, as well as the volume and function of the remnant liver. A suggested flowchart to guide treatment decision-making in the setting of recurrent disease is presented in Figure 1.

| Author          | Year | Type of Study | Selection Criteria | Overall Survival | Disease-Free Survival | Mortality | Major Complications |
|-----------------|------|---------------|--------------------|------------------|-----------------------|-----------|--------------------|
| Table 1 Recent Studies Comparing Treatment Modalities in Patients with Recurrent Hepatocellular Carcinoma |
| Repeat liver resection versus RFA |
| Xia et al19 | 2020 | RCT | Early disease (BCLC 0/A) | Comparable 5-year OS (43.6% vs 38.5%, p=0.15) | Comparable 5-year DFS (52.4% vs 41.7%, p=0.09) | None | Increased (22.4% vs 7.3%, p=0.001) |
| Zhong et al20 | 2021 | Retrospective -PSM | N/a | Comparable 5-year OS (56.4% vs 53.1%, p=0.6) | Increased 5-year DFS (25.5% vs 16%, p<0.001) | Comparable (0.9% vs 0.4%, p=1) | Increased (19 vs 5.3, p<0.001) |
| Wei et al31 | 2021 | Retrospective -PSM | Early disease (BCLC 0/A) | Comparable 5-year OS (59% vs 71.4%, p=0.36) | Comparable 5-year DFS (32.4% vs 34%, p=0.78) | N/a | Comparable (p=0.62) |
| Feng et al37 | 2020 | Retrospective -PSM | Up to three nodules, ≤5 cm | Comparable 5-year OS (38.1% vs 55.6%, p=0.11) | Comparable 5-year DFS (14.6% vs 19.2%, p=0.78) | None | Increased (9.1% vs 0.5%, p<0.001) |
| Lu et al61 | 2020 | Retrospective -PSM | None | Increased 5-year PRS (71.8% vs 41.7%, p=0.002) | None | None | N/a |
| Salvage liver resection after previous radiofrequency ablation vs repeat hepatectomy after previous liver resection |
| Yamashita et al62 | 2015 | Retrospective | N/a | Decreased 5-year OS (52%, p=0.02) | Decreased 3-year DFS (p=0.02) | None | Increased (26% vs 4%, p<0.1) |

(Continued)
Liver resection is often the index operation for primary HCC, and similarly should be considered for recurrent disease in the proper clinical setting. Repeat resection is generally preferable – when feasible – to ablation or TACE for recurrent HCC. Decisions about resection versus ablation/TACE need, however, to consider multiple factors; clinical decisions about treatment should involve size and location of the lesion, as well as the underlying liver function. Ablation has the advantage of being percutaneous and potentially less morbid. Whether repeat resection or ablation confers equivalent long-term survival has been debated. In a propensity-score matched analysis, Chua et al noted that ablation and repeat resection were equivalent with respect to short-term survival \((p=0.84)\); however, repeat hepatectomy was associated with superior 3-, 5-, and 10-year survival compared with ablation.\(^{55}\) Patients who underwent repeat hepatectomy also experienced improved DFS \((p=0.02)\), yet had higher 30-day morbidity and mortality compared with patients who underwent ablation. Therefore, the authors concluded repeat resection was associated with a higher peri-operative risk of complications and death, yet a higher chance at long-term survival compared with ablation. Other studies have failed, however, to confirm a long-term survival benefit of repeat resection over ablation.\(^{20,56,57}\)

### Table 1 (Continued)

| Author          | Year | Type of Study | Selection Criteria | Overall Survival | Disease-Free Survival | Mortality | Major Complications |
|-----------------|------|---------------|--------------------|------------------|-----------------------|-----------|---------------------|
| Yamagishi et al\(^{63}\) | 2019 | Retrospective | N/a                | Decreased 5-year OS \((41.8\% \text{ vs } 63.2\%, \text{ } p=0.02)\) | Comparable 5-year DFS rate \((10.3\% \text{ vs } 15.9\%, \text{ } p=0.4)\) | Comparable \((1.8\% \text{ vs } 0, \text{ } p=1)\) | Comparable \((27.7\% \text{ vs } 31.4\%, \text{ } p=0.83)\) |
| Ma et al\(^{69}\) | 2018 | Retrospective -PSM | UCSF              | Increased 5-year OS \((71.6\% \text{ vs } 32.8\%, \text{ } p<0.001)\) | Increased 5-year DFS \((72.8\% \text{ vs } 48.3\%, \text{ } p=0.007)\) | Comparable \((0 \text{ vs } 1.9\%, \text{ } p>0.99)\) | Comparable \((16\% \text{ vs } 8.3\%, \text{ } p=0.21)\) |
| Chan et al\(^{68}\) | 2013 | Retrospective | Within Milan criteria | Increased 5-year OS \((60\% \text{ vs } 48\%, \text{ } p=0.004)\) | Increased 5-year DFS \((57.9\% \text{ vs } 49.3\%, \text{ } p<0.001)\) | N/a       | N/a                 |
| Wang et al\(^{54}\) | 2020 | Retrospective | Tumor size ≤3 cm, ≤3 tumors | Comparable 3-year OS \((68.8\% \text{ vs } 45\%, \text{ } p=0.49)\) | Increased 3-year PFS \((p=0.004)\) | None      | None                |
| Gou et al\(^{53}\) | 2022 | Meta-analysis | N/a                | Increased odds for 5-year OS \((OR=3.22, 95\% \text{ CI}=1.34–7.72, \text{ } p=0.009)\) | N/a       | N/a                 | Comparable \((OR=1.78, 95\% \text{ CI}=0.55–5.78, \text{ } p=0.33)\) |

**Abbreviations:** RFA, radiofrequency ablation; TACE, transarterial chemoembolization; OS, overall survival; DFS, disease-free survival; OR, odds ratio; CI, confidence interval; RCT, randomized controlled trial; PSM, propensity-score matching; BCLC, Barcelona Clinic Liver Cancer staging system.

### Repeat Resection versus Other Treatments

Liver resection is often the index operation for primary HCC, and similarly should be considered for recurrent disease in the proper clinical setting. Repeat resection is generally preferable – when feasible – to ablation or TACE for recurrent HCC. Decisions about resection versus ablation/TACE need, however, to consider multiple factors; clinical decisions about treatment should involve size and location of the lesion, as well as the underlying liver function. Ablation has the advantage of being percutaneous and potentially less morbid. Whether repeat resection or ablation confers equivalent long-term survival has been debated. In a propensity-score matched analysis, Chua et al noted that ablation and repeat resection were equivalent with respect to short-term survival \((p=0.84)\); however, repeat hepatectomy was associated with superior 3-, 5-, and 10-year survival compared with ablation.\(^{55}\) Patients who underwent repeat hepatectomy also experienced improved DFS \((p=0.02)\), yet had higher 30-day morbidity and mortality compared with patients who underwent ablation. Therefore, the authors concluded repeat resection was associated with a higher peri-operative risk of complications and death, yet a higher chance at long-term survival compared with ablation. Other studies have failed, however, to confirm a long-term survival benefit of repeat resection over ablation.\(^{20,56,57}\) The comparability of repeat
resection and ablation relative to long-term outcomes following treatment of recurrent HCC was particularly pronounced among patients with early recurrence. In particular, several studies have noted no difference in outcomes following repeat resection versus ablation among patients with recurrent HCC who met Milan criteria or had early-stage disease according
to the Barcelona Clinic Liver Cancer (BCLC) classification. In particular, patients with recurrent tumors less than 3 cm had no difference in post-treatment outcomes following resection versus ablation, yet ablation was associated with a lower incidence of complications. In contrast, patients with recurrences outside the Milan criteria did better in terms of post-recurrence survival after repeat hepatic resection. Collectively, these data strongly suggest that resection should be preferred in eligible patients with recurrent disease larger than 3–5 cm, while ablation may be considered for smaller-sized recurrent disease.

A subset of patients with primary HCC is sometimes initially managed by ablation. When recurrence occurs post-ablation, “salvage” liver surgery can sometimes be considered. In fact, this approach (ie, ablation followed by salvage resection) may be preferable in some patients as it may allow for better selection of candidates for resection (ie, a “step-up” approach from less invasive to more invasive treatments). Yamashita et al evaluated 46 patients who underwent salvage liver resection for HCC recurrence following ablation. In this study, the authors compared outcomes of patients who underwent ablation followed by salvage resection with patients who underwent a second liver resection following an index hepatectomy for HCC. Of note, patients who underwent the “step-up” approach had worse DFS and OS than patients who had an initial resection followed by a second liver resection. These data are hard to interpret, however, due to the lack of propensity-score matching and the considerable imbalances in patient baseline and tumor variables, which precluded any robust conclusions. In a separate study, Yamagishi et al examined the efficacy of salvage liver resection using propensity score matching (n=54, ablation followed by salvage resection vs n=54 resection followed by second hepatectomy). While median OS was worse in the salvage liver resection group (4.4 years versus 5.6 years, respectively; p<0.02), median DFS was comparable. In addition, the incidence of complications and mortality were equivalent between the two different treatment modality groups. Despite data suggesting worse survival among patients who underwent salvage hepatectomy, no previous study adequately controlled for all confounders. In turn, further investigation and careful case-control matching is required to elucidate better the role of salvage resection following ablation in the management of recurrent HCC.

Salvage Liver Transplantation
The presence of cirrhosis is a major limiting factor in considering repeat hepatectomy for recurrent HCC. For patients with poor underlying liver reserve, orthotopic liver transplantation (OLT) may be an option to treat recurrent HCC. OLT yields excellent oncologic outcomes in the treatment of primary HCC. However, the scarcity of available organs and the increased logistic requirements limit its applicability in the setting of recurrent HCC. Salvage liver transplantation (SLT) after HCC recurrence following hepatectomy has been demonstrated to provide acceptable outcomes. While no randomized trials exist to compare SLT with repeat resection, a number of observational studies and meta-analyses have demonstrated superior DFS with SLT rather than repeat resection for recurrent HCC. For example, in one meta-analysis, Wang et al analyzed 840 patients across 7 retrospective studies and concluded that SLT was associated with improved 3-year (OR 3.23, 95% CI 1.45–7.20) and 5-year (OR 4.79, 95% CI 1.88–12.2) DFS compared with repeat hepatectomy for recurrent HCC. Nevertheless, no difference in OS was observed between the two groups. In a different meta-analysis, Zheng et al ranked all treatment modalities for recurrent HCC with respect to OS and DFS. Of note, SLT was associated with significantly better DFS compared with all other treatment modalities including repeat hepatectomy, stereotactic beam radiotherapy (SBRT), ablation, and TACE; yet, no significant differences in OS were noted between SLT and repeat hepatectomy for recurrent HCC. In contrast, other studies have noted better OS following SLT versus resection for recurrent HCC, especially among patients matched with respect to MELD score. While no official guidelines currently exist to recommend SLT in the setting of recurrent HCC, a number of institutions currently apply the Milan or UCSF criteria to identify candidates for SLT. Given the scarcity of available organs, repeat resection remains the mainstay of treatment for patients with resectable HCC recurrence and adequate liver function, while SLT is largely reserved for individuals who develop cirrhosis following hepatectomy for primary HCC or have unresectable disease but meet transplantation criteria.

Systemic and Combination Therapies
Advanced recurrent HCC usually refers to lesions that are not amenable to curative-intent treatments either due to tumor multicentricity, tumor size, presence of extrahepatic disease, vascular invasion, or poor performance status. When recurrent disease is not amenable to locoregional treatments, systemic therapy should be considered. Although there are increasing
data on the effectiveness of various systemic therapies in primary advanced HCC, data focusing on advanced recurrent HCC are limited. Based on the recent data from the IMBrave150 clinical trial, the combination of atezolizumab with bevacizumab was demonstrated to be superior to sorafenib among patients with advanced HCC and, thus, is currently considered first-line treatment for this patient group based on the latest Barcelona Clinic Liver Cancer (BCLC) guidelines. Given the recent update in the BCLC guidelines, there are currently no official recommendations as to what should represent the second-line treatment following atezolizumab-bevacizumab. Second-line treatment for individuals with advanced-stage HCC who failed to respond and/or progressed on sorafenib include regorafenib (for individuals tolerant to sorafenib), cabozantinib (irrespective of tolerance to sorafenib), or ramucirumab (if AFP levels are >400 ng/dL, irrespective of tolerance to sorafenib). Although these recommendations largely apply to patients with primary HCC, the BCLC guidelines can be extrapolated and utilized as treatment guide for individuals with recurrent HCC. In addition, several new-generation molecular inhibitors that target MET, VEGFR, FGF, and AXL tyrosine kinases are now being tested, yet have not proved better than best supportive care. Despite the ongoing research in the field of targeted therapies, none of the newer agents has been officially recommended in the setting of recurrent HCC either as stand-alone or as adjunct treatment modality.

Other investigators have examined the combination of systemic therapies with ablation and/or TACE in the setting of advanced recurrent HCC. In one study, Peng et al retrospectively evaluated the efficacy of combined ablation, TACE, and sorafenib therapy versus sorafenib alone among 207 patients with advanced recurrent HCC. Patients with extrahepatic recurrence and right or left portal vein invasion were mainly included in the analysis, which demonstrated a prolonged median OS (14 vs 9 months, \( p<0.001 \)) and time to disease progression (7.0 vs 4.0 months, \( p<0.001 \)) with trimodality treatment compared with sorafenib monotherapy. In addition, Jiang et al performed a meta-analysis of 21 studies. This report demonstrated that bimodality with ablation and TACE treatment was associated with better survival outcomes than any other modality alone. Of note, however, the addition of TACE to RFA for lesions less than 3 cm did not seem to provide any additive benefit.

**Conclusion**

HCC is an aggressive disease with more than one-half of patients developing recurrence despite stage-appropriate treatment. A multitude of risk factors for recurrence following curative-intent treatment of primary HCC have been identified in the literature, most of which relate to the size, number of primary lesions, presence of lymphovascular invasion, as well as the presence of underlying liver cirrhosis. Irrespective of adverse characteristics of disease and type of primary treatment employed, close surveillance in the postoperative period is of paramount importance especially during the first two years following curative-intent treatment. More than half of patients will develop a recurrence and will require re-evaluation of disease status given that a second curative-intent treatment holds the best chance for disease control and long-term survival. Careful staging of recurrent HCC patients is important and should take into account the characteristics of the tumor itself (ie, number of lesions and size), as well as patient performance status and underlying liver function at the time of recurrence. Current data suggest that a size cut-off of 3 cm could be applied to characterize very early recurrent HCC that could potentially be managed by less invasive modalities such as ablation, while the Milan criteria remain relevant in the recurrent setting pertaining to the selection of candidates for SLT. Multimodal treatment for recurrent HCC appears to provide a benefit to assess oncologic outcomes. As researchers continue to share their experiences regarding the treatment and outcomes of patients with recurrent HCC, well-designed prospective studies with appropriate patient matching will undoubtedly bring more insight regarding which criteria can be used to further optimize treatment decision-making at the time of HCC recurrence.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Sharma R. Descriptive epidemiology of incidence and mortality of primary liver cancer in 185 countries: evidence from GLOBOCAN 2018. Jpn J Clin Oncol. 2020;50(12):1370–1379. doi:10.1093/jjco/hyaa130
2. Brar G, Greten TF, Graubard BI, et al. Hepatocellular carcinoma survival by etiology: a SEER-medicare database analysis. Hepatol Commun. 2020;4(10):1541–1551. doi:10.1002/hepc.41564
3. Tsilimigras DI, Bagante F, Moris D, et al. Recurrence patterns and outcomes after resection of hepatocellular carcinoma within and beyond the Barcelona clinic liver cancer criteria. Ann Surg Oncol. 2020;27(7):2321–2331. doi:10.1245/s10434-020-08452-3
4. Shah SA, Cleary SP, Wei AC, et al. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery. 2007;141(3):330–339. doi:10.1016/j.surg.2006.06.028
5. Vitale A, Farinati F, Finotti M, et al. Overview of prognostic systems for hepatocellular carcinoma and ITA.LICA external validation of MESH and CNLC classifications. Cancers. 2021;13(7):1673. doi:10.3390/cancers13071673
6. Ding J, Wen Z. Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database. BMC Cancer. 2021;21(1):1157. doi:10.1186/s12885-021-02894-3
7. Papaconstantinou D, Hewitt DB, Brown ZJ, Schizas D, Tsilimigras DJ, Pawlik TM. Patient stratification in hepatocellular carcinoma: impact on choice of therapy. Expert Rev Anticancer Ther. 2022;22(3):297–306. doi:10.1080/14772560.2022.2041415
8. Raitan R, Azzeri A, Shabaruddin HF, Mohamed R. Hepatocellular carcinoma in Malaysia and its changing trend. Euroasian J Hepatogastroenterol. 2018;8(1):54–56. doi:10.5005/jp-journals-10018-1259
9. El-Kassas M, Elbadry M. Hepatocellular carcinoma in Africa: challenges and opportunities. Front Med. 2022;9:899420. doi:10.3389/fmed.2022.899420
10. Kawamura Y, Arase Y, Ikekawa K, et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma. J Am Gastroenterol. 2012;107(2):253–261. doi:10.1038/jamag.2011.327
11. El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 2014;60(5):1767–1775. doi:10.1002/hep.27222
12. Xu XF, Xing H, Han J, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China. JAMA Surg. 2019;154(3):209–217. doi:10.1001/jamasurg.2018.4334
13. Zhang K, Tao C, Wu F, Wu J, Rong W. A practical nomogram from the SEER database to predict the prognosis of hepatocellular carcinoma in patients with lymph node metastasis. Am Palliat Med. 2021;10(4):3847–3863. doi:10.21037/apm-20-1876
14. Tsilimigras DJ, Mehta R, Guglielmi A, et al. Recurrence beyond the Milan criteria after curative-intent resection of hepatocellular carcinoma: a novel tumor-burden based prediction model. J Surg Oncol. 2020;122(5):955–963. doi:10.1002/jso.26901
15. Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol. 2020;72(2):250–261. doi:10.1001/jhep.2019.08025
16. Tan DJH, Wong C, Ng CH, et al. Patterns of recurrence following liver transplantation: a study from China. J Hepatol. 2014;61(5):1038–1045. doi:10.1016/j.jhep.2014.04.046
17. Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol. 2020;72(2):250–261. doi:10.1001/jhep.2019.08025
18. Tan DJH, Hong W, Ng CH, et al. Meta-analysis of the rate of hepatocellular carcinoma recurrence after liver transplant and associations to etiology, alpha-fetoprotein, income and ethnicity. J Clin Med. 2021;10(2):238. doi:10.3390/jcm10020238
19. Kim HJ, An J, Kim JY, et al. Postresection period-specific hazard of recurrence as a framework for surveillance strategy in patients with hepatocellular carcinoma: a multicenter outcome study. Liver Cancer. 2022;11(2):141–151. doi:1159/000518837
20. Lee S, Hyuck David Kwon C, Kim J, et al. Time of hepatocellular carcinoma recurrence after liver resection and alpha-fetoprotein are important prognostic factors for salvage liver transplantation. Liver Transplant. 2014;20(9):1057–1063. doi:10.1002/lt.23919
21. Xiao Y, Li J, Liu G, et al. Long-term effects of repeat hepatocytomy vs percutaneous radiofrequency ablation among patients with recurrent hepatocellular carcinoma: a randomized clinical trial. JAMA Oncol. 2020;6(2):255–263. doi:10.1001/jamaoncol.2019.4477
22. Zhong J-H, Xing B-C, Zhang W-G, et al. Repeat hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: retrospective multicentre study. Br J Surg. 2021;109(1):71–78. doi:10.1093/bjsi/zxab340
23. Yamashita Y, Shirabe K, Tsuijita E, et al. Third or more repeat hepatectomy for recurrent hepatocellular carcinoma. Surgery. 2013;154(5):1038–1045. doi:10.1016/j.surg.2013.04.046
24. Xie Q-S, Chen Z-X, Zhao Y-J, Gu H, Geng X-P, Liu F-B. Systematic review of outcomes and meta-analysis of risk factors for hepatocellular carcinoma recurrence following liver transplantation. World J Gastrointest Oncol. 2019;11(4):322–334. doi:10.4251/wjgo.v11.i4.322
25. Feng J, Wu J, Zou R, et al. Simple risk score for prediction of early recurrence of hepatocellular carcinoma within the Milan criteria after orthotopic liver transplantation. Scit Rep. 2017;7(1):44036. doi:10.1038/srep44036
26. Hasan B, Colak Y, Khalid RA, et al. Early detection of hepatocellular carcinoma recurrence in the posttransplant population: a comparison of RETREAT and Cleveland Florida transplating cohort. Transplant Proc. 2021;53(1):193–199. doi:10.1016/j.transproceed.2020.09.015
27. He YZ, He K, Huang RQ, et al. A clinical scoring system for predicting tumor recurrence after percutaneous radiofrequency ablation for 3 cm or less hepatocellular carcinoma. Sci Rep. 2021;11(1):8275. doi:10.1038/s41598-021-87782-y
28. Liu Z, Liu Y, Zhang W, et al. Deep learning for prediction of hepatocellular carcinoma recurrence after resection or liver transplantation: a discovery and validation study. Hepatol Int. 2022;16:3–10. doi:10.1111/hei.15307
29. Facchiono A, Del Prete V, Antonino M, et al. Post-recurrence survival in hepatocellular carcinoma after percutaneous radiofrequency ablation. Dig Liver Dis. 2014;46(11):1014–1019. doi:10.1016/j.dld.2014.07.012
30. C-M H, Lee C-H, Lee M-C, et al. Survival after treatable hepatocellular carcinoma recurrence in liver recipients: a nationwide cohort analysis. J Gastrointest Surg. 2021;25(1):125–133. doi:10.1007/s11605-020-04553-2
31. Saito R, Amemiya H, Hosomura N, et al. Prognostic factors for post-recurrent survival in hepatocellular carcinoma after curative resection. Anticancer Res. 2019;39(6):3033 LP-3038. doi:10.21873/anticancerres.13436
32. Vogel A, Martellini E. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO clinical practice guidelines. Ann Oncol. 2021;32(6):801–805. doi:10.1093/annonc/mdab014
33. Liu X, Jiang H, Chen J, Zhou Y, Huang Z, Song B. Gad oxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: a meta-analysis. Liver Transplant. 2017;23(12):1505–1518. doi:10.1002/lt.24867
34. Min JH, Kim YK, Choi S-Y, et al. Detection of recurrent hepatocellular carcinoma after surgical resection: non-contrast liver MR imaging with diffusion-weighted imaging versus gadoxetic acid-enhanced MR imaging. Br J Radiol. 2018;91(9900):20180177. doi:10.1259/brj.20180177
36. Kim W-J, Lim T-W, Park P-J, Choi S-B, Kim W-B. Prognostic markers affecting the early recurrence of hepatocellular carcinoma with liver cirrhosis after curative resection. *Int J Mol Sci*. 2019;20(12):2986. doi:10.3390/ijms20122986

37. Wang B-L, Tan Q-W, Gao X-H, Wu J, Guo W. Elevated PIVKA-II is associated with early recurrence and poor prognosis in BCLC 0-A hepatocellular carcinomas. *Asian J Cancer Prev*. 2014;15(16):6673–6678. doi:10.3141/apcj.2014.15.16.6673

38. Q-Y Q, Wang X-Q, Fan G, et al. Value of AFP and PIVKA-II in diagnosis of HBV-related hepatocellular carcinoma and prediction of vascular invasion and tumor differentiation. *Infect Agent Cancer*. 2020;15(1):70. doi:10.1186/s13027-020-00337-0

39. Takada Y, Ito T, Ueda M, et al. Living donor liver transplantation for patients with HCC exceeding the Milan criteria: a proposal of expanded criteria. *Dig Dis*. 2007;25(4):299–302. doi:10.1159/000010690

40. Duda DG, Dima SO, Cucu D, et al. Potential circulating biomarkers of recurrence after hepatic resection or liver transplantation in hepatocarcinoma patients. *Cancers*. 2020;12(5):1275. doi:10.3390/cancers12051275

41. Ye K, Fan Q, Yuan M, et al. Prognostic value of postoperative circulating tumor DNA in patients with early- and intermediate-stage hepatocellular carcinoma. *Front Oncol*. 2022;12:834992. doi:10.3389/fonc.2022.834992

42. Ji J, Wang H, Li Y, et al. Diagnostic evaluation of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatitis B virus-related hepatocellular carcinoma in China: a large-scale, multicentre study. *PLoS One*. 2016;11(4):e0153227. doi:10.1371/journal.pone.0153227

43. Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. *Hepatology*. 2018;67(1):358–380. doi:10.1002/hep.29086

44. Yoon JH, Lee WJ, Kim SM, et al. Simple parameters predicting extrahepatic recurrence after curative hepatectomy for hepatocellular carcinoma. *Sci Rep*. 2021;11(1):12984. doi:10.1038/s41598-021-92503-6

45. Midorikawa Y, Takayama T, Nakayama H, et al. Favorable outcomes of surgical resection for extrahepatic recurrent hepatocellular carcinoma. *Hepatol Res*. 2020;50(8):978–984. doi:10.1111/hepr.13526

46. Yao S-Y, Liang B, Chen-Y-Y, Tang Y-T, Dong X-F, Liu T-Q. Clinical stages of recurrent hepatocellular carcinoma: a retrospective cohort study. *World J Clin Cases*. 2021;9(27):8020–8026. doi:10.21037/wjcc.v9.i27.8020

47. Yao T, Tang YY, Yao T-J, Fan S-T, Lo C-M, Poon RTP. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. *Gastroenterology*. 2014;146(7):761–700.e3. doi:10.1053.j.gastro.2014.02.032

48. Tsilimigras DI, Moris D, Hyer JM, et al. Serum α-fetoprotein levels at time of recurrence predict post-recurrence outcomes following resection of hepatocellular carcinoma. *Ann Surg Oncol*. 2021;28(12):7673–7683. doi:10.1245/s10434-021-09977-x

49. Kim H-S, N-J Y, Kim JM, Joh J-W, Lee K-W, Suh K-S. Clinical impact of the treatment modality on small, solitary, recurrent hepatocellular carcinomas after primary liver resection. *Ann Surg Oncol*. 2021;28(10):85–92. doi:10.1245/s10434-021-09977-x

50. Fanularo S, Donadon M, Cipriani F, et al. Curative versus palliative treatments for recurrent hepatocellular carcinoma: a multicentric weighted comparison. *HPB*. 2021;23(6):889–898. doi:10.1016/j.hpb.2020.10.007

51. Liu L, Zhang Q, Geng J, et al. Comparison of radiofrequency ablation combined with sorafenib or sorafenib alone in patients with ECOG performance score 1: identifying optimal candidates. *Ann Transl Med*. 2020;8(9):583. doi:10.21037/atm.2020.03.71

52. Zhao S, Dou W, Fan Q, et al. Identifying optimal candidates of transarterial chemoembolization (TACE) vs. sorafenib in patients with unrespectable hepatocellular carcinoma. *Ann Transl Med*. 2020;8(9):587. doi:10.21037/atm.2020.02.123

53. Gou H, Liu S, Zhu G, et al. Effectiveness of radiofrequency ablation versus transarterial chemoembolization for recurrent hepatocellular carcinoma: a meta-analysis. *Acta Radiol Open*. 2022;11(3):2058601221085510. doi:10.1177/2058601221085514

54. Wang X, Liang H, Lu Z. Efficacy of transarterial chemoembolization compared with radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma after radiofrequency ablation. *Minin Invasive Ther Allied Technol*. 2020;29(6):345–352. doi:10.1080/13645706.2019.1649286

55. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med*. 2006;355(11):1–20. doi:10.1056/NEJMoa055531

56. Wei F, Huang Q, Zhou Y, Luo L, Zeng Y. Radiofrequency ablation versus repeat hepatectomy in the treatment of recurrent hepatocellular carcinoma in subcapsular location: a retrospective cohort study. *World J Surg Oncol*. 2021;19(1):175. doi:10.1186/s12957-021-02777-4

57. Feng Y, Wu H, Huang DQ, et al. Radiofrequency ablation versus repeat resection for recurrent hepatocellular carcinoma (≤ 5 cm) after initial curative resection. *Eur Radiol*. 2020;30(11):6357–6368. doi:10.1007/s00330-020-06990-8

58. Mazzaferrro V, Bhoori S, Sposito C, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. *Liver Transplant*. 2011;17(Suppl 2):S44–57. doi:10.1002/lt.22365

59. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. *Semin Liver Dis*. 1999;19(3):329–338. doi:10.1055/s-2007-1007122

60. Yang Y, Yu H, Tan X, et al. Liver resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: a systematic review and meta-analysis. *Int J Hyperth*. 2021;38(1):875–886. doi:10.1080/02665736.2021.1933218

61. L-H L, Mei J, Kan A, et al. Treatment optimization for recurrent hepatocellular carcinoma: repeat hepatic resection versus radiofrequency ablation. *Cancer Med*. 2020;9(9):2997–3005. doi:10.1002/cam4.2951

62. Yamashita S, Aoki T, Inoue Y, et al. Outcome of salvage hepatic resection for recurrent hepatocellular carcinoma after radiofrequency ablation therapy. *Surgery*. 2015;157(3):463–472. doi:10.1016/j.surg.2014.10.019

63. Yanagishi S, Midorikawa Y, Nakayama H, et al. Liver resection for recurrent hepatocellular carcinoma after radiofrequency ablation therapy. *Hepatol Res*. 2019;49(4):432–440. doi:10.1111/hepr.13293

64. Menahem B, Lubrano J, Duvoux C, et al. Liver transplantation versus liver resection for hepatocellular carcinoma in intention to treat: an attempt to perform an ideal meta-analysis. *Liver Transplant*. 2017;23(6):836–844. doi:10.1002/lt.24758

65. Zhang X, Li C, Wen T, Peng W, Yan L, Yang J. Treatment for intrahepatic recurrence after curative resection of hepatocellular carcinoma: salvage liver transplantation or resection/radiofrequency ablation therapy? A Retrospective Cohort Study. *Int J Surg*. 2017;46:178–185. doi:10.1016/j.ijsu.2017.09.001

66. Wang H-L, Mo D-C, Zhong J-H, et al. Systematic review of treatment strategy for recurrent hepatocellular carcinoma: salvage liver transplantation or curative locoregional therapy. *Medicine*. 2019;98(8):e14498. doi:10.1097/MD.00000000000014498

67. Zheng J, Cai J, Tao L, et al. Comparison on the efficacy and prognosis of different strategies for intrahepatic recurrent hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis. *Int J Surg*. 2020;83:196–204. doi:10.1016/j.ijsu.2020.09.031
68. Chan ACY, Chan SC, Chok KSH, et al. Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency ablation? *Liver Transplant*. 2013;19(4):411–419. doi:10.1002/lt.23605
69. Ma KW, Chok KSH, She WH, et al. Defining optimal surgical treatment for recurrent hepatocellular carcinoma: a propensity score matched analysis. *Liver Transplant*. 2018;24(8):1062–1069. doi:10.1002/lt.25033
70. Sposito C, Mariani L, Germini A, et al. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. *J Hepatol*. 2013;59(1):59–66. doi:10.1016/j.jhep.2013.02.026
71. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. *N Engl J Med*. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
72. Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. *J Hepatol*. 2022;76(3):681–693. doi:10.1016/j.jhep.2021.11.018
73. Abou-Alfa GK, Meyer T, Cheng A-L, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. *N Engl J Med*. 2018;379(1):54–63. doi:10.1056/NEJMoa1717002
74. Zhu AX, Finn RS, Mulcahy M, et al. A Phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. *Clin Cancer Res*. 2013;19(23):6614–6623. doi:10.1158/1078-0432.CCR-13-1442
75. Llovet JM, Decaens T, Raoul J-L, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized Phase III BRISK-PS study. *J Clin Oncol*. 2013;31(28):3509–3516. doi:10.1200/JCO.2012.47.3009
76. Peng Z, Chen S, Wei M, et al. Advanced recurrent hepatocellular carcinoma: treatment with sorafenib alone or in combination with transarterial chemoembolization and radiofrequency ablation. *Radiology*. 2018;287(2):705–714. doi:10.1148/radiol.201818171541
77. Jiang C, Cheng G, Liao M, Huang J. Individual or combined transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma: a time-to-event meta-analysis. *World J Surg Oncol*. 2021;19(1):81. doi:10.1186/s12957-021-02188-4